MRNA vs NXT · rev $145.0M vs P/E 32, rev $3.56B
Moderna Inc (MRNA) versus Nextracker Inc. Class A Common Stock (NXT) — a side-by-side from cached financials, not a winner call.
Moderna Inc (MRNA) is a biotechnology company listed on NASDAQ. It is led by Stephane Bancel.
Nextracker Inc. Class A Common Stock (NXT) is a solar company listed on NASDAQ.
Latest reported MRNA revenue for 2026-06-30 was $145.0M. Net income was -$782.0M. Revenue was down 62.7% from 2026-03-31 to 2026-06-30. MRNA currently screens at market cap $24.52B.
Latest reported NXT revenue for 2026-03-31 was $3.56B. Net income was $585.9M. Revenue was up 20.3% from 2025-03-31 to 2026-03-31. NXT currently screens at market cap $18.77B and trailing P/E 32.1.
MRNA currently screens at market cap $24.52B. NXT currently screens at market cap $18.77B and trailing P/E 32.1.
Not investment advice. Open the MRNA and NXT stock pages for the full models.
Not investment advice.